Medical Marijuana Competitive Intelligence Analysis report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the Medical Marijuana Market industry. A detailed picture of the competitive landscape is provided with summation of data from multiple sources with complete analysis of companies, patents, pipeline products, competitive benchmarking and therapeutic assessment of clinical products.

The fast development of the cannabis and its expanding appropriation over the therapeutic application has grabbed the eye of a large group of industry verticals running from pharmaceuticals to land and preparing ventures to advisory and consultancy administrations. While cannabis cultivators and producers are the most critical piece of the cannabis ecosystem, revenue comes significantly from Pharmaceutical organizations.

The U.S. Food and Drug Administration (FDA) has not recognized or approved the marijuana plant as medicine. However, the scientific study of the chemicals in marijuana, called cannabinoids, has led to some FDA-approved medications that contain cannabinoid chemicals in pill form. Continued research may lead to the approval of more medications.

The medical marijuana market report covers 12+ companies working in this domain, such as GW Pharmaceuticals, Canopy Growth Corporation, Aurora Cannabis, Auxly Cannabis Group and others. GW Pharmaceuticals has two medical marijuana products in the market; Epidiolex and Sativex. Epidiolex (cannabidiol) oral solution is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.

By Haadi